Literature DB >> 9531478

Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.

G C Sui1, B Wiman.   

Abstract

Thirteen amino acid substitutions have been introduced within the stretch Phe113 to Asp138 in the plasminogen activator inhibitor 1 (PAI-1) molecule by site-directed mutagenesis. The different proteins and wild-type (wt) PAI-1 have been overexpressed in Escherichia coli and purified by chromatography on heparin-Sepharose and on anhydrotrypsin-agarose. The PAI-1 variants have been characterized by their reactivity with tissue plasminogen activator (tPA), interactions with vitronectin or heparin, and stability. Most PAI-1 variants, except for Asp125-->Lys, Phe126-->Ser and Arg133-->Asp, displayed a high spontaneous inhibitory activity towards tPA, which did not change greatly on reactivation with 4 M guanidinium chloride, followed by dialysis at pH 5.5. The variants Asp125-->Lys and Arg133-->Asp became much more active after reactivation and they were also more rapidly transformed to inactive forms (t12 22-31 min) at physiological pH and temperature than the other variants. However, in the presence of vitronectin they were both almost equally stable (t12 2.3 h) as wtPAI-1 (t12 3.0 h). The mutant Glu130-->Lys showed an increased stability, both in the absence and in the presence of vitronectin compared with wtPAI-1. Nevertheless a similar affinity between all the active PAI-1 variants and vitronectin was observed. Further, all mutants, including the three mutants with low activity, were to a large extent adsorbed on anhydrotrypsin-agarose and were eluted in a similar fashion. In accordance with these data, the three variants with a low activity were all to a large extent cleaved as a result of their reaction with tPA, suggesting that they occurred predominantly in the substrate conformation. Our results do not support the presence of a binding site for vitronectin in this part of the molecule, but rather that it might be involved in controlling the active PAI-1 to substrate transition. Partly, this region of the PAI-1 molecule (Arg115 to Arg118) seems also to be involved in the binding of heparin to PAI-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531478      PMCID: PMC1219369          DOI: 10.1042/bj3310409

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.

Authors:  D A Lawrence; L Strandberg; J Ericson; T Ny
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

2.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.

Authors:  E L Madison; E J Goldsmith; R D Gerard; M J Gething; J F Sambrook; R S Bassel-Duby
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma.

Authors:  B Wiman; A Almquist; O Sigurdardottir; T Lindahl
Journal:  FEBS Lett       Date:  1988-12-19       Impact factor: 4.124

4.  Stability of plasminogen activator inhibitor 1 (PAI-1).

Authors:  T L Lindahl; O Sigurdardottir; B Wiman
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

5.  Thrombosis after hip replacement. Relationship to the fibrinolytic system.

Authors:  B I Eriksson; E Eriksson; E Gyzander; A C Teger-Nilsson; B Risberg
Journal:  Acta Orthop Scand       Date:  1989-04

6.  Complex formation between plasminogen activator inhibitor 1 and vitronectin in purified systems and in plasma.

Authors:  O Sigurdardóttir; B Wiman
Journal:  Biochim Biophys Acta       Date:  1990-07-20

7.  Mutational and immunochemical analysis of plasminogen activator inhibitor 1.

Authors:  H E Shubeita; T L Cottey; A E Franke; R D Gerard
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

8.  Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.

Authors:  J D York; P Li; S J Gardell
Journal:  J Biol Chem       Date:  1991-05-05       Impact factor: 5.157

9.  Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.

Authors:  H J Ehrlich; J Keijer; K T Preissner; R K Gebbink; H Pannekoek
Journal:  Biochemistry       Date:  1991-01-29       Impact factor: 3.162

10.  Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium.

Authors:  T Lindahl; B Wiman
Journal:  Biochim Biophys Acta       Date:  1989-02-23
View more
  1 in total

1.  Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.

Authors:  P R Elliott; X Y Pei; T R Dafforn; D A Lomas
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.